Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors. We studied the reversal effect of AA for these inhibitors in various anticoagulant and thrombin generation (TG) assa...

Full description

Bibliographic Details
Main Authors:	Fakiha Siddiqui BDS, Alfonso Tafur MD, Lorenzo Storino Ramacciotti BS, Walter Jeske PhD, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Omer Iqbal MD, FACC, FESC, Jawed Fareed PhD
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-07-01
Series:	Clinical and Applied Thrombosis/Hemostasis
Online Access:	https://doi.org/10.1177/1076029619863493

Similar Items

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-01-01)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-12-01)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
by: Fakiha Siddiqui BDS, et al.
Published: (2019-05-01)

Porcine Mucosal Heparin Shortage Crisis! What Are the Options?
by: Jawed Fareed PhD, et al.
Published: (2019-09-01)

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
by: Fakiha Siddiqui BDS, et al.
Published: (2020-10-01)

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study
by: Nina Haagenrud Schultz MD, PhD, et al.
Published: (2021-05-01)

Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?
by: Nil Guler MD, et al.
Published: (2020-07-01)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
by: Elise Carpenter, et al.
Published: (2019-11-01)

Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins
by: Ahmed Kouta MS, MBA, et al.
Published: (2019-11-01)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
by: Kaatz S, et al.
Published: (2017-09-01)

Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy
by: Amanda Walborn PhD, et al.
Published: (2020-03-01)

Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version
by: Dalia Qneibi MD, et al.
Published: (2020-09-01)

Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation
by: Amanda Walborn PhD, et al.
Published: (2019-05-01)

Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy
by: Gracelene Wegrzyn MD, et al.
Published: (2021-02-01)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
by: Victoria M. Stevens PharmD, BCCCP, et al.
Published: (2021-09-01)

Antidotes for the new oral anticoagulant drugs!
by: Jawed Fareed, et al.
Published: (2019-01-01)

Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation
by: Priya Patel BS, et al.
Published: (2019-04-01)

Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review
by: Nicholas Kipshidze MD, PhD, DSc, et al.
Published: (2020-09-01)

Right ventricular pacing-induced cardiomyopathy: Is there a role for blood biomarkers?
by: Dimitris Tousoulis, MD PhD FESC FACC, et al.
Published: (2020-07-01)

Factor Xa Inhibition, A New Strategy for Prevention of Adverse Cardiac Remodeling in Early Stages?∗
by: Biykem Bozkurt, MD, PhD
Published: (2020-01-01)

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
by: Victoria M. Stevens PharmD, et al.
Published: (2019-12-01)

MRI in all MR patients: Is this the “Gold Standard” approach?
by: Constantina Aggeli, MD, PhD, FESC, et al.
Published: (2016-11-01)

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?
by: Eduardo Ramacciotti MD, PhD, et al.
Published: (2019-06-01)

Interrelationship of MMP-9, Proteoglycan-4, and Inflammation in Osteoarthritis Patients Undergoing Total Hip Arthroplasty
by: Hannah Slovacek BS, et al.
Published: (2021-03-01)

Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase
by: Aleksander Druck BS, et al.
Published: (2019-12-01)

Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling
by: Emily Bontekoe BS, et al.
Published: (2021-05-01)

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
by: Tessa Jaspers, et al.
Published: (2021-05-01)

Pulmonary and intracranial miliary tuberculosis secondary to Behçet's anti-TNF alfa treatment
by: Asmae Sekkat, MD, et al.
Published: (2021-02-01)

Viral Coagulopathy in Patients With COVID-19: Treatment and Care
by: Nickolas Kipshidze MD, PhD, DSc, et al.
Published: (2020-07-01)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism
by: Trung Phan MD, et al.
Published: (2020-01-01)

Socioeconomic status and risk factors for cardiovascular disease: Impact of dietary mediators
by: Theodora Psaltopoulou, MD PhD, et al.
Published: (2017-01-01)

A short RP tachycardia with alternating ventriculoatrial interval, but identical atrial activation sequence: What is the mechanism?
by: Yasuyuki Egami, MD, et al.
Published: (2020-08-01)

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination
by: Bulent Kantarcioglu MD, et al.
Published: (2021-05-01)

Zika and Chikungunya Virus and Risk for Venous Thromboembolism
by: Eduardo Ramacciotti MD, PhD, et al.
Published: (2019-01-01)

Regulation of Cortisol in Patients Undergoing Total Joint Arthoplasty
by: Rajan Khanna MD, et al.
Published: (2021-04-01)

Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates
by: Ahmed Kouta MS, MBA, et al.
Published: (2021-04-01)

Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates
by: Ahmed Kouta MS, MBA, et al.
Published: (2020-10-01)

Interrelationship of Osteopontin, MMP-9 and ADAMTS4 in Patients With Osteoarthritis Undergoing Total Joint Arthroplasty
by: Hannah Slovacek BS, et al.
Published: (2020-12-01)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
by: C. James Watson, et al.
Published: (2019-11-01)

Bipolar ablation of high-risk posteroseptal accessory pathway: Back to the future
by: Piotr Futyma, MD, PhD, et al.
Published: (2020-03-01)